In NAFLD, particularly indole pathway metabolites, converted by the gut microbiome, have been shown to reduce inflammation via the NF-kB pathway and several other metabolites have been shown to reduce the production of cytokines such as IL-22 and modulate the innate immune system [26]. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.